Events

AGM 2024.

Ascelia Pharma will give an investor update - please see link below to watch the event and send your questions prior to the event: Investor Update - Bringing Orviglance to patients

If you wish to participate via webcast, please use the link below. You can ask written questions through the webcast: https://ir.financialhearings.com/ascelia-pharma-q1-report-2024

Magnus Corfitzen will present the Q1 interim report. To register to the event: Ascelia Pharma - What happened during Q1 2024  

Ascelia Pharma will present at the Carnegie Healthcare Conference.

Ascelia Pharma will present at the HC Andersen Life Science Seminar, to attend: https://www.inderes.dk/videos/life-science-seminar-2024

Julie Waras Brogren, Deputy CEO will present the commercial and partnership strategy for Orviglance, to register and submit your questions: Ascelia Pharma commercial and partnership strategy

Julie Waras Brogren will present the Q2 interim report at a virtual live event for investors. To register:  Update Q2 2024

Magnus Corfitzen will present at Cargenie. The presentation will be live streamed: Ascelia Pharma Live Presentation  

Magnus Corfitzen will present the final outcome of the Rights issue. You can already sign up for the event: Ascelia Pharma Final Outcome Of Rights Issue  

Julie Waras Brogren, Deputy CEO will present Q3 2024 results. To register to the event: Ascelia Pharma - What Happened During Q3 2024

Ascelia Pharma will be at the Jefferies Healthcare conference.

Ascelia Pharma will present Orviglance SPARKLE study primary results as oral presentation in cutting edge research at the 2024 RSNA annual meeting. Timing of presentation: 2 Dec, 13:30-14:00 CDT, local time Chicago  

Ascelia Pharma will present at the institutional investor seminar, to register: investor seminar registration

Ascelia Pharma will present at the Redeye Fight Cancer Event. You can send in your question: Ask your questions